Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.63 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.63 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.61 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 4/20 | 0.60 |
| ▸ | CALCR | P30988 | 4/20 | 0.56 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182512 | 0.87 | CALCR (0.64) | CRHR1CRHR2F2CALCRHCRTR1 | |
| SCHEMBL30950135 | 0.87 | CALCR (0.57) | CRHR1CRHR2CALCRC5AR1 | |
| Angiotensin Ii SCHEMBL29361861 | 0.86 | AGTR2 (0.82) | AGTR2AGTR1F2 | |
| SCHEMBL30431276 | 0.86 | CALCR (0.64) | CRHR1CRHR2F2CALCRHCRTR1 | |
| SCHEMBL31462342 | 0.86 | CALCR (0.56) | AGTR2AGTR1CRHR1CRHR2F2 | |
| SCHEMBL31462347 | 0.85 | CALCR (0.56) | AGTR2AGTR1CRHR1CRHR2F2 | |
| SCHEMBL31462340 | 0.85 | CALCR (0.56) | AGTR2AGTR1CRHR1CRHR2F2 | |
| SCHEMBL29546394 | 0.85 | CALCR (0.56) | CRHR1CRHR2CALCRC5AR1 | |
| SCHEMBL29811060 | 0.85 | CALCR (0.66) | AGTR2AGTR1CRHR1CRHR2F2 | |
| SCHEMBL30554076 | 0.85 | F2 (0.63) | AGTR2AGTR1CRHR1CRHR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196958-A2 | TUMOR AND CANCER TARGETING COMPOUNDS | ONCOLINX PHARMACEUTICALS (US) | 2023-10-12 | — | — | WO | claimed |
| US-11440936-B2 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | ENTERIN, INC. (US) | 2022-09-13 | — | — | US | claimed |
| US-20220220148-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAME | ENTERIN INC. (US) | 2022-07-14 | — | — | US | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | ENTERIN, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4168399-B1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | NANJING IMMUNOPHAGE BIOMEDICAL CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-12569556-B2 | Aluminum based adjuvants for tolerogenic vaccination | EAST CAROLINA UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| US-12503501-B2 | Treatment of central nervous system disorders by intranasal administration of immunoglobulin G | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-12-23 | — | — | US | disclosed |
| US-11440936-B2 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | ENTERIN, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-11426465-B2 | Hydrazinyl-indole compounds and methods for producing a conjugate | Redwiid Bioscience, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220220148-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAME | ENTERIN INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-11376334-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220153696-A1 | Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-05-19 | — | — | US | disclosed |
| US-20220145270-A1 | Antibody Conjugates and Methods of Making and Using the Same | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-05-12 | — | — | US | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153696-A1 | Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate | DNPEP, QPCT, PDS5A | AGTR2 3977/4885AGTR1 4090/4885CRHR1 3232/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | AGTR2 617/4885AGTR1 580/4885CRHR1 513/4885 |
| US-11414405-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | AGTR2 3602/4885AGTR1 4204/4885CRHR1 1968/4885 |
| US-11426465-B2 | Hydrazinyl-indole compounds and methods for producing a conjugate | HNMT, AANAT, INMT | AGTR2 3115/4885AGTR1 3357/4885CRHR1 1710/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | AGTR2 526/4885AGTR1 312/4885CRHR1 46/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | AGTR2 1608/4885AGTR1 883/4885CRHR1 1521/4885 |
| US-20220220148-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAME | SI, VIP, ASNS | AGTR2 685/4885AGTR1 1073/4885CRHR1 374/4885 |
| US-11440936-B2 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | SI, VIP, ASNS | AGTR2 685/4885AGTR1 1073/4885CRHR1 374/4885 |
| US-11376334-B2 | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate | HNMT, TIAL1, HACL2 | AGTR2 2816/4885AGTR1 3173/4885CRHR1 4162/4885 |
| US-20260098052-A1 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | HSD3B1, HSD3B2, HSD11B1 | AGTR2 167/4885AGTR1 95/4885CRHR1 54/4885 |
| US-12569556-B2 | Aluminum based adjuvants for tolerogenic vaccination | IFNG, MYH2, MYH10 | AGTR2 2294/4885AGTR1 1843/4885CRHR1 4542/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | AGTR2 1134/4885AGTR1 539/4885CRHR1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.